We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

tDCS and Aphasia Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01922245
Recruitment Status : Unknown
Verified August 2015 by Elizabeth Galletta, PhD, Hunter College.
Recruitment status was:  Recruiting
First Posted : August 14, 2013
Last Update Posted : August 19, 2015
Information provided by (Responsible Party):
Elizabeth Galletta, PhD, Hunter College

Brief Summary:
This project will investigate the use of noninvasive brain stimulation in the form of tDCS (transcranial direct current stimulation) in conjunction with speech-language therapy, for the improvement of language production in stroke survivors with aphasia. The hypothesis is that anodal tDCS and speech-language therapy will facilitate improved outcomes compared to speech therapy alone.

Condition or disease Intervention/treatment
Aphasia Device: Soterix 1x1 tDCS

Detailed Description:

Aphasia, commonly defined as impairment or loss of language functions, is a frequent and often chronic consequence of stroke, with detrimental effects on patient autonomy and health-related quality of life (HRQOL). Although beneficial in some cases, the effectiveness of behavioral therapy is often limited, and therefore new complementary treatments must be developed in order to improve rehabilitation of post-stroke aphasia.

In most individuals, language areas in the brain are localized in the left hemisphere. After stroke, there is evidence that the brain reorganizes such that either areas close to damaged language areas in the Left Hemisphere, or anatomically similar areas in the Right Hemisphere, are recruited to perform language tasks.

Recently, studies have begun to examine the effects of non-invasive brain stimulation on aphasia rehabilitation. One such technique is transcranial direct current stimulation (tDCS), which involves administering weak electrical currents through surface electrodes on the scalp. The effects can either stimulate an area, or inhibit an area of the brain. The main hypothesis is that stimulating language areas in the Left Hemisphere in conjunction with speech language therapy will facilitate reorganization of language-relevant areas of the brain, and improve expression.

The proposed study will compare the effects of transcranial direct current stimulation (tDCS) activating language centers in the Left Hemisphere and sham tDCS, in right-handed individuals with chronic post-stroke aphasia. This study will provide information on the effects of tDCS, in conjunction with speech-language therapy, on aphasia rehabilitation.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: tDCS and Aphasia Treatment
Study Start Date : July 2013
Estimated Primary Completion Date : January 2016
Estimated Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aphasia
U.S. FDA Resources

Arm Intervention/treatment
Experimental: anodal tDCS
Soterix 1x1 device: anodal tDCS administered to the left hemisphere
Device: Soterix 1x1 tDCS
Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.

Primary Outcome Measures :
  1. change in naming performance in singles words and sentence context [ Time Frame: change from baseline naming performance at two weeks and four weeks post treatment ]
    Naming will be tested using standardized tests such at the Boston Naming Test and or the Philadelphia Naming Test. In addition, sentence probes have been created that will assess naming in the sentence context throughout the study.

Secondary Outcome Measures :
  1. change in sentence production [ Time Frame: change from baseline performance at two weeks and four weeks post treatment ]
    Sentence production will be classified.

  2. change in health related quality of life [ Time Frame: change from baseline performance at two weeks and four weeks post treatment ]
    Scales of health related quality of life will be implemented.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: single left hemisphere stroke, more than three months post stroke, right handed, no other medical problems, ages 18-100 -

Exclusion Criteria: more than one stroke, less than three months post stroke, other medical problems, pacemaker or other electronic implant (e.g. hip replacement), pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01922245

Contact: Elizabeth Galletta, PhD 914-481-4439 elizabeth.galletta@gmail.com
Contact: Amy Vogel, BA 212-481-4439 amy.vogel@gmail.com

United States, New York
Hunter College Brookdale Campus Recruiting
New York, New York, United States, 10010
Contact: Elizabeth Galletta, PhD    212-481-4439    elizabeth.galletta@gmail.com   
Principal Investigator: Elizabeth Galletta, PhD         
Sponsors and Collaborators
Hunter College of City University of New York
Principal Investigator: Elizabeth E Galletta, PhD Hunter College/City University of NY

Responsible Party: Elizabeth Galletta, PhD, Assistant Professor, Hunter College
ClinicalTrials.gov Identifier: NCT01922245     History of Changes
Other Study ID Numbers: 062951
First Posted: August 14, 2013    Key Record Dates
Last Update Posted: August 19, 2015
Last Verified: August 2015

Keywords provided by Elizabeth Galletta, PhD, Hunter College:
quality of life

Additional relevant MeSH terms:
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms